Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2707-2714

  Ferro, Paola ^a   Canessa, Pier Aldo ^b   Battolla, Enrico ^c   Dessanti, Paolo ^a   Franceschini, Maria Cristiana ^a   Chiaffi, Luigi ^b   Morabito, Anna ^d   Fontana, Vincenzo ^d   Pezzi, Riccardo ^d   Fedeli, Franco ^a   Pistillo, Maria Pia ^d   Roncella, Silvio ^a  

^a Division of Histopathology and Cytopathology   (Italy)

^b Division of Pneumology   (Italy)

^c Division of Clinical Pathology ASL5   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Malignant pleural effusion; Mesomark assay; Mesothelin; Pleural mesothelioma

Indexed keywords

MESOTHELIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THORACOCENTESIS; AGED; BLOOD; LUNG TUMOR; MALIGNANT PLEURAL EFFUSION; MESOMARK ASSAY; MESOTHELIOMA; METASTASIS; MIDDLE AGED; PLEURA TUMOR; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK; THORACOSCOPY; VERY ELDERLY;

MALIGNANT PLEURAL EFFUSION; MESOMARK ASSAY; MESOTHELIN; PLEURAL MESOTHELIOMA;

AGED; AGED, 80 AND OVER; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM METASTASIS; ODDS RATIO; PLEURAL EFFUSION; PLEURAL NEOPLASMS; PROGNOSIS; ROC CURVE; THORACOSCOPY; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84881409918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aziz T, Jilaihawi A and Prakash D: The management of malignant pleural mesothelioma; Single centre experience in 10 years. Eur J Cardiothorac Surg 22: 298-305, 2002.
2. Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R and Ardissone F: Malignant pleural mesothelioma: Clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 33: 307-313, 2008.
3. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and Sorahan T: Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89: 716-724, 2011.
4. Fazzo L, Minelli G, De Santis M, Bruno C, Zona A, Marinaccio A, Conti S, Pirastu R and Comba P: Mesothelioma mortality surveillance and asbestos exposure tracking in Italy. Ann Ist Super Sanita 48: 300-310, 2012.
5. Gennaro V, Ugolini D, Viarengo P, Benfatto L, Bianchelli M, Lazzarotto A, Montanaro F and Puntoni R: Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002). Eur J Cancer 41: 2709-2714, 2005.
6. Ismail-Khan R, Robinson LA, Williams CC Jr., Garrett CR, Bepler G and Simon GR: Malignant pleural mesothelioma: A comprehensive review. Cancer Control 13: 255-263, 2006.
7. Neragi-Miandoab S: Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54: 1-9, 2006.
8. Light RW: The undiagnosed pleural effusion. Clin Chest Med 27: 309-319, 2006.
9. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F and Metintas S: Medical thoracoscopy vs. CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: A randomized, controlled trial. Chest 137: 1362-1368, 2010.
10. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP and Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol 19: 92-8, 2010.
11. Ray M and Kindler HL: Malignant pleural mesothelioma: An update on biomarkers and treatment. Chest 136: 888-896, 2009.
12. Greillier L, Baas P, Welch JJ, Hasan B and Passioukov A: Biomarkers for malignant pleural mesothelioma: Current status. Mol Diagn Ther 12: 375-390, 2008.
13. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996.
14. Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197, 2003.
15. Tang Z, Qian M and Ho M: The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem 13: 276-280, 2013.
16. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI and Sardesai NY: MESOMARK: A potential test for malignant pleural mesothelioma. Clin Chem 53: 666-672, 2007.
17. Dipalma N, Luisi V, Di Serio F, Fontana A, Maggiolini P, Licchelli B, Mera E, Bisceglia L, Galise I, Loizzi M, Pizzigallo MA, Molinini R and Vimercati L: Biomarkers in malignant mesothelioma: Diagnostic and prognostic role of soluble mesothelin-related peptide. Int J Biol Markers 26: 160-165, 2011.
18. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L and Puntoni R: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13: 5076-5081, 2007.
19. Luo L, Shi HZ, Liang QL, Jiang J, Qin SM and Deng JM: Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-Analysis. Respir Med 104: 149-156, 2010.
20. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T and Dienemann H: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 3: 1317-1324, 2008.
21. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE and Hellstrom I: Mesothelinfamily proteins and diagnosis of mesothelioma. Lancet 36: 1612-1616, 2003.
22. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M and Liu G: Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 28: 3316-3122, 2010.
23. Yamada S, Tabata C, Tabata R, Fukuoka K and Nakano T: Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 49: 1721-1726, 2011.
24. Aleman C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S and de Sevilla TF: Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Med Clin 133: 449-453, 2009.
25. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ and Robinson BW: Soluble mesothelin in effusions: A useful tool for the diagnosis of malignant mesothelioma. Thorax 62: 569-576, 2007.
26. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL and Lee YC: Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 180: 437-444, 2009.
27. Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B and Maskell NA: A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir J 41: 18-24, 2012.
28. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H and Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173: 1155-1160, 2006.
29. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M and Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265-272, 2008.
30. Canessa PA, Franceschini MC, Ferro P, Battola E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP and Roncella S: Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: Its contribution to cytology. Cancer Invest 31: 43-50, 2013.
31. Pepe MS: The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, UK: Oxford University Press, 2003.
32. Glas AS, Lijmer JG, Prins MH, Bonsel GJ and Bossuyt PM: The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 56: 1129-1135, 2003.